KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $182.1 million.

  • Royalty Pharma's Operating Expenses rose 20689.68% to $182.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $817.2 million, marking a year-over-year increase of 1315.69%. This contributed to the annual value of $971.1 million for FY2024, which is 1260.75% up from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Operating Expenses is $182.1 million, which was up 20689.68% from $368.9 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Operating Expenses ranged from a high of $1.0 billion in Q4 2022 and a low of -$190.0 million during Q2 2021
  • Over the past 5 years, Royalty Pharma's median Operating Expenses value was $282.7 million (recorded in 2021), while the average stood at $274.1 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first tumbled by 28701.99% in 2021, then skyrocketed by 147940.93% in 2024.
  • Royalty Pharma's Operating Expenses (Quarter) stood at $422.3 million in 2021, then surged by 148.27% to $1.0 billion in 2022, then crashed by 101.61% to -$16.8 million in 2023, then skyrocketed by 1479.41% to $232.1 million in 2024, then dropped by 21.54% to $182.1 million in 2025.
  • Its Operating Expenses stands at $182.1 million for Q3 2025, versus $368.9 million for Q2 2025 and $34.1 million for Q1 2025.